NEW YORK, NY / ACCESSWIRE / March 28, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Nephros, Inc. (OTCQB: NEPH).

The report is available here: NEPH Update Note.

Based in River Edge, NJ, Nephros, Inc. (OTCQB: NEPH “Nephros”) is a commercial stage medical device company, with innovative filtration products targeting large market opportunities including hospital infection control and advanced renal care. Nephros was founded by two healthcare professionals associated with Columbia University Medical Center / New York Presbyterian Hospital to develop a hemodiafiltration (HDF) device as an alternative to hemodialysis. Nephros has developed proprietary technology to accomplish this goal, and in addition to commercializing an HDF System, Nephros has also developed advanced filtration devices for a variety of applications where ultrapure filtration is of potential value.

Investment Highlights

On March 17, 2017, Nephros reported full year 2017 results, with highlights as follows:

Revenues grew by 19% in 2016 to reach $2.3mn, versus $1.9m in 2015

Product revenues of 2.1mn rose by 17%, while License & Royalty revenue increased by 47% YoY from a small base.

NEPH received 510(k) clearance for new 10″ filters for HydraGuard™ for infection control and EndoPur™ for hemodialysis.

EPS narrowed to ($0.06) for the year, versus ($0.09) in 2015.

Nephros management guided to growing product revenues by 100% in 2017 based on new products, and set a goal of reaching cash flow breakeven by mid-2017.

Solid 4Q16 results to end the year

Nephros ended 2016 with a solid performance in the 4Q. Despite having much of management’s efforts focused on regulatory submissions and new product development / introductions, the company managed to grow its overall business by 19.3% during the year, with controlled operating expenses. Product revenues grew sharply in 4Q16, in particular, during which they rose by 40% sequentially. Growth was due to the launch of the new S100 point of use filters with rising demand for hospital infection control products. For the full year 2016, revenues came in at $2.3mn versus $1.9mn in 2015.

Encouraging guidance on new products, targeting cash flow

Nephros CEO, Daron Evans issued an encouraging outlook when the company released 2016 results. Evans stated that the company is now targeting positive cash flow within six months, as Nephros is expected to benefit from rising product revenues. Significant drivers are expected to be continued distribution of the S100, as well as the launch of HydraGuard™ for infection control, which received FDA 510(k) clearance in December. Additionally, Nephros received regulatory clearance for the new 10″ EndoPur™ filter for use in hemodialysis in March, and is planning to launch this product in 2Q17.

Price target unchanged at $1.65

We are leaving our price target for Nephros unchanged at this time at $1.65. We view Nephros as an intriguing high risk / high reward investment opportunity in the medical instruments industry with several potential catalysts in 2017 stemming from growth from new product launches and guidance for reaching cash flow breakeven in the next six months.

Please review important disclosures on our website at www.seethruequity.com.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients. http://www.nephros.com

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 458342

LONDON, UK / ACCESSWIRE / March 28, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Banking industry. Companies recently under review include The Toronto-Dominion Bank, Atrium Mortgage Investment, Laurentian Bank of Canada, and Royal Bank of Canada. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

On Monday, March 27, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,506.22, 0.41% higher, with a total volume of 311,391,482 shares.

Additionally, the Financials index was slightly up by 0.13%, ending the session at 288.58.

Active Wall St. has initiated research reports on the following equities: The Toronto-Dominion Bank (TSX: TD), Atrium Mortgage Investment Corporation (TSX: AI), Laurentian Bank of Canada (TSX: LB), and Royal Bank of Canada (TSX: RY). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

The Toronto-Dominion Bank

Canada headquartered The Toronto-Dominion Bank’s stock edged 0.08% lower, to finish Monday’s session at $65.13. Toronto-Dominion Bank’s shares have gained 16.80% in the past one year. The Company’s shares are trading above its 200-day moving average. The Toronto-Dominion Bank’s 50-day moving average of $68.03 is above its 200-day moving average of $64.09. Shares of the Company, which together with its subsidiaries, provides various personal and commercial banking products and services in Canada, the US, and internationally, are trading at a PE ratio of 13.51. See our research report on TD.TO at:

http://www.activewallst.com/register/

Atrium Mortgage Investment Corp.

On Monday, shares in Toronto, Canada headquartered Atrium Mortgage Investment Corp. recorded a trading volume of 39,569 shares. The stock ended the day 0.90% lower at $12.06. Atrium Mortgage Investment’s stock has advanced 4.24% in the past one year. The Company’s shares are trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $12.05 is above its 50-day moving average of $12.01. Shares of the Company, which provides financing solutions to the real estate communities in Ontario, Saskatchewan, Alberta, and British Columbia in Canada, are trading at PE ratio of 12.63. The complimentary research report on AI.TO at:

http://www.activewallst.com/register/

Laurentian Bank of Canada

On Monday, shares in Montréal, Canada headquartered Laurentian Bank of Canada ended the session 0.46% higher at $58.60 with a total volume of 67,888 shares traded. Laurentian Bank of Canada’s shares have gained 21.65% in the past one year. The stock is trading above its 200-day moving average. Furthermore, the stock’s 50-day moving average of $59.37 is greater than its 200-day moving average of $54.84. Shares of Laurentian Bank, which together with its subsidiaries, provides banking services to individuals, small and medium-sized enterprises, and independent advisors in Canada, are trading at a PE ratio of 12.98. Register for free and access the latest research report on LB.TO at:

http://www.activewallst.com/register/

Royal Bank of Canada

Toronto, Canada headquartered Royal Bank of Canada’s stock closed the day 0.25% higher at $96.79. The stock recorded a trading volume of 2.94 million shares, which was above its three months average volume of 2.57 million shares. Royal Bank of Canada’s shares have advanced 0.07% in the last one month and 5.44% in the past three months. Furthermore, the stock has gained 20.78% in the previous one year. The company’s shares are trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $97.25 is greater than its 200-day moving average of $89.75. Shares of the Company, which together with its subsidiaries, operates as a diversified financial service company worldwide, are trading at a PE ratio of 13.51. Get free access to your research report on RY.TO at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458303

Upcoming AWS Coverage on Patheon Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 28, 2017 / Active Wall St. blog coverage looks at the headline from Allergan PLC (NYSE: AGN) and Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) as both Companies announced on March 27, 2018, positive results for the two Phase-3 trials of sarecycline for the treatment of moderate to severe acne. Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting. Based on these data, Allergan plans to file a New Drug Application (NDA) to the US Food & Drug Administration (FDA) in H2 2017. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Allergan’s competitors within the Drugs – Generic space, Patheon N.V. (NYSE: PTHN), reported on March 16, 2017, its financial results for the quarter ended January 31, 2017. AWS will be initiating a research report on Patheon in the coming days.

Today, AWS is promoting its blog coverage on AGN and PRTK; touching on PTHN. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Trial Results

The Company’s two phase-II study SC1401 & SC1402 were designed to be replicative phase-3 randomized, multicenter, double-blind, placebo-controlled studies to evaluate the efficacy and safety of 1.5 mg/kg per day of sarecycline compared to placebo in the treatment of moderate to severe acne.

The primary objective was to evaluate the efficacy and safety of oral sarecycline 1.5 mg/kg per day compared to placebo in treating inflammatory acne lesions in subjects with moderate to severe acne based on Investigators Global Assessment (IGA) scale score and inflammatory lesion counts. Patients were randomized (1:1) into two treatment groups to receive either sarecycline tablets (60 mg, 100 mg, and 150 mg, providing a dose of 1.5 mg/kg/day) or placebo once a day for 12 weeks.

The companies stated that Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints. The most common adverse events reported in the sarecycline group were nausea, nasopharyngitis, and headache. The rate of discontinuation due to adverse events among sarecycline-treated patients in the two studies combined was 1.4%.

“The positive efficacy results observed in the pivotal phase-3 clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne,” said David Nicholson, Chief Global Research & Development Officer at Allergan, “We look forward to submitting a new drug application for sarecycline and bringing to market a potential new option for physicians treating patients with acne.”

“We are pleased with the results of the sarecycline Phase-3 program and Allergan’s intention to move ahead with an NDA submission for approval in the US by the end of 2017,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer of Paratek Pharma, “Sarecycline is a narrow spectrum antibiotic, which we believe can offer meaningful clinical benefits for patients afflicted with acne.”

Allergan owns the rights for the development and commercialization of sarecycline in US, while Paratek Pharma retains all non-US global rights.

Paratek’s lead product candidate, Omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative, and atypical bacteria. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the US FDA for several indications.

Stock Performance

At the close of trading session on Monday, March 27, 2017, Allergan’s stock price rose slightly by 0.86% to end the day at $239.38. A total volume of 2.51 million shares were exchanged during the session. The Company’s share price has gained 23.75% in the past three months and 14.31% on YTD basis. The stock currently has a market cap of $85.32 billion and has a dividend yield of 1.17%.

Paratek’s stock price surged 9.15% from its previous closing price of $15.85, finishing yesterday’s trading session at $17.30. A total of 2.21 million of Company’s share were exchanged during the day. Paratek’s stock price has gained 14.57% in the past one month and has advanced 17.69% in the last one year. The Company’s shares have a market cap of $458.28 million based on Monday’s closing price.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458301

Upcoming AWS Coverage on SAP SE

LONDON, UK / ACCESSWIRE / March 28, 2017 / Active Wall St. announces its post-earnings coverage on Oracle Corp. (NYSE: ORCL). The Company announced its financial results for the first quarter fiscal 2017 (Q3 FY17) on March 15, 2017. The Redwood Shores, California-based Company’s quarterly non-GAAP total revenues and diluted EPS rose on a year-over-year basis, beating market consensus estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Oracle’s competitors within the Application Software space, SAP SE (NYSE: SAP), is estimated to report earnings on April19, 2017. AWS will be initiating a research report on SAP SE following the release of its next earnings results.

Today, AWS is promoting its earnings coverage on ORCL; touching on SAP. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

In Q3 FY17, Oracle reported GAAP total revenues of $9.21 billion compared to $9.01 billion recorded at the end of Q3 FY16. The Company’s non-GAAP total revenues increased 3% during Q3 FY17 to $9.27 billion from $9.01 billion in Q3 FY16. Non-GAAP total revenues numbers for the reported quarter has outperformed market expectations of $9.23 billion.

The software developer reported Q3 FY17 GAAP net income of $2.24 billion, or $0.53 per diluted share, versus $2.14 billion, or $0.50 per diluted share, in Q3 FY16. Moreover, the Company’s non-GAAP net income for Q3 FY17 came in at $2.89 billion, or $0.69 per diluted share, compared to $2.73 billion, or $0.64 per diluted share in the last year quarter. The Company’s non-GAAP diluted earnings per share also outperformed market earnings estimates of $0.62 per diluted share.

Operating Metrics

During the three months ended on February 28, 2017, the Company’s GAAP total operating expenses were $6.25 billion compared to $5.99 billion in Q3 FY16. In Q3 FY17, non-GAAP total operating expenses came in at $5.33 billion compared to $5.19 billion in Q3 FY16. The Company’s GAAP operating income for Q3 FY17 stood at $2.96 billion, or 32% of GAAP total revenues versus $3.03 billion, or 34% of GAAP total revenues, in Q3 FY16. Moreover, the Company’s non-GAAP operating income increased during Q3 FY17 to $3.94 billion, or 43% of non-GAAP total revenues, from $3.82 billion, or 42% of non-GAAP total revenues, in the previous year’s quarter.

Segment Performance

During Q3 FY17, total cloud revenues surged 62% y-o-y to $1.19 billion from $735 million in Q3 FY16. Meanwhile, the Company’s total on-premise software revenues were down by 3% to $6.18 billion in Q3 FY17 from $6.35 billion in Q3 FY16. Furthermore, total hardware revenues declined 9% y-o-y in Q3 FY17 to $1.03 billion from $1.14 billion in Q3 FY16. However, total services revenues grew 2% to $812 million in Q3 FY17 from $793 million in Q3 FY16.

Geographical Contribution

In Q3 FY17, Americas, the largest market for Oracle, generated revenues of $5.22 billion, up from $4.94 billion in Q3 FY16. Revenues from Asia/Pacific region was $1.43 billion in Q3 FY17, rising from $1.41 billion in the prior year’s comparable quarter. However, revenues from Europe, Middle East, Africa regions fell to $2.56 billion in Q3 FY17 from $2.66 billion in Q3 FY16.

Cash Flow & Balance Sheet

For the nine months ended on February 28, 2017, Oracle generated $9.66 billion in cash from operations compared to $9.89 billion at the end of three quarters in the year ago same period. The Company had cash and cash equivalents balance of $19.75 billion as on February 28, 2017, compared to $20.15 billion, at the close of books on May 31, 2016.

Dividend and Share Repurchases

In its earnings press release, Oracle’s Board of Directors announced a 27% hike in quarterly dividend to $0.19 per share of outstanding common stock. The dividend is payable on April 26, 2017, to shareholder of record at the close of business on April 12, 2017.

During the reported quarter, Oracle repurchased 30 million shares for a total of $500 million. Furthermore, in the last 12 months, the Company repurchased a total of 124 million shares for a total of $5 billion and paid out dividends of $2.5 billion.

Stock Performance

On Monday, March 27, 2017, the stock closed the trading session at $44.84, slightly up 0.43% from its previous closing price of $44.65. A total volume of 8.93 million shares have exchanged hands. Oracle’s stock price rallied 3.87% in the last month, 15.54% in the past three months, and 15.19% in the previous six months. Moreover, the stock surged 17.08% since the start of the year. The Company’s shares are trading at a PE ratio of 21.20 and have a dividend yield of 1.43%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458309

Visitors to PeakWilderness.com Can Read In-Depth and Helpful Reviews on Dozens of Products Ranging from Survival Watches and Camping Knives to Tactical Flashlights and More

LOS ANGELES, CA / ACCESSWIRE / March 28, 2017 / The founders of PeakWilderness.com, a website that is devoted to helping people survive their time in the wilderness, are pleased to announce that they are now providing expert reviews on the latest survival and outdoors gear. In addition, the website now offers helpful tips and advice on being in the outdoors.

To check out the in-depth and unbiased reviews as well as learn more about Peak Wilderness, please visit http://www.peakwilderness.com/ at any time.

As a company spokesperson noted, even though the reviews on Peak Wilderness were only recently posted, they are already getting a lot of positive attention from visitors to the website.

For example, a new review that focuses on some of the Best Survival Watches has been especially popular with people who are eager to learn more about this essential outdoor tool. While some survival watches look like designer pieces of jewelry, others have a much-more rugged appearance. In either case, the new review notes, a survival watch can be an invaluable tool when exploring the wilderness.

In reviewing one of the survival watches that received a positive rating, the reviewer first admits to being skeptical about any product that claims to offer everything a person could want in an outdoor tool. However, after looking into it further, it did seem to deliver on this promise.

The survival watch features a number of built-in tools including a variety of survival accessories like a compass, whistle, striker, fishing line and hooks and safety pins, as well as an affordable price and water resistance.

Another review that is creating quite a buzz with visitors to the Peak Wilderness website focuses on the Best Camping Knife. Whether someone is camping near a car or is hunkered down miles into the woods, having a top quality camping knife is essential. The review covers a wide variety of camping knives, including fixed blade, and those that include a number of blades for clearing brush, skinning game and trimming wood.

About Peak Wilderness:

Peak Wilderness is the premier site for news, tips and reviews on survival and the outdoors. People who are looking for information to help them with their next outdoor adventure or who need gear will find everything they need at the user-friendly website. For more information, please visit http://www.peakwilderness.com/.

Contact:

Mark Francis

admin@rocketfactor.com
(949) 555-2861

SOURCE: Peak Wilderness

ReleaseID: 458329

VANCOUVER, BC / ACCESSWIRE / March 28, 2017 / Zinc One Resources Inc. (TSXV: Z) (“Zinc One”) and Forrester Metals Inc. (TSXV: VEM.H) (“Forrester”) are pleased to announce, further to their news release on February 1, 2017 and March 7, 2017, that Forrester has obtained an interim order of the Ontario Superior Court of Justice in connection with the proposed plan of arrangement (the “Arrangement”). The interim order provides for, among other things, the holding of a special meeting (the “Special Meeting”) of the holders of common shares of Forrester (the “Shareholders”) to approve the Arrangement under the Ontario Business Corporations Act. The Special Meeting is scheduled to be held at the offices of Forrester, 130 King Street West, Suite 3680, Toronto, Ontario M5X 1B1 on Monday, April 24, 2017 at 10:00 a.m. (Toronto time). The record date for determining Shareholders entitled to receive notice of and vote at the Special Meeting was fixed at the close of business on March 20, 2017.

As previously disclosed, Forrester entered into an arrangement agreement with Zinc One pursuant to which Zinc One will acquire all of the issued and outstanding common shares of Forrester and, upon closing, Forrester will become a wholly owned subsidiary of Zinc One. Forrester’s directors and senior officers have agreed to support the Arrangement and vote their common shares in favor of the Arrangement. The Board of Directors of Forrester has previously approved the Arrangement and has unanimously recommended that Shareholders approve the Arrangement.

The completion of the Arrangement is subject to certain conditions, including the receipt of the requisite approval from the Shareholders, the final approval (the “Final Order”) of the Ontario Superior Court of Justice at an application which is scheduled for April 26, 2017, final acceptance by the respective stock exchanges on which Forrester and Zinc One trade, and other closing conditions customary in transactions of this nature. If all necessary approvals are obtained and the conditions to the completion of the Arrangement are satisfied or waived, it is currently anticipated that the Arrangement will be completed on or about April 30, 2017.

About Bongará Zinc Mine and Charlotte Bongará Zinc Project

The Bongará Zinc Mine zinc-oxide mineralization was discovered in 1974 and since then various companies have completed exploration programs across the area. The mineralization is concentrated along and proximal to a NW-trending anticlinal axis over approximately 2.5 kilometres. From the southeast edge of the project, the Mina Grande, Mina Chica and Bongarita mine areas were subject to sampling from pits and trenches as well as shallow drilling over a distance of approximately 1.2 kilometres. This zinc-oxide mineralization appears to continue to the northwest into an additional exploration area known as Campo Cielo, where additional high grade, zinc-oxide mineralization in historical pits and trenches.

The adjacent Charlotte Bongará Zinc Project was explored by Solitario Resources in 1994. Cominco Ltd. later completed five drill holes for 592 metres within the property, two of which encountered near-surface, high grade zinc oxide mineralization. Between 2007 and 2011, Rio Cristal Zinc optioned the project and eventually drilled 95 drill holes for a total of 7,722 metres on the Cristal and Charlita prospects. Rio Cristal drill results included 29.5% Zn across 15.5 metres, 26.1% Zinc across 12.5 metres, 29.7% Zinc across 11.5 metres (the cited intervals are drill-intercept widths and true widths are unknown).

About Zinc One Resources Inc.

Zinc One is a Vancouver based company focused on the acquisition, exploration and development of prospective and advanced zinc projects. Zinc One believes in the current and future fundamentals of the zinc supply and demand scenario and the continued growing demand for zinc in global industrial uses.

About Forrester Metals Inc.

Forrester Metals is a Canadian mining company focused on the exploration and development of Peru’s mineral potential. Forrester has six projects including two zinc properties, Azulcocha West and the Bongará Zinc Mine and the Charlotte Bongará Zinc Project.

The technical content of this news release has been reviewed and approved by James Walchuck, CEO and director of Zinc One, and Bill Williams, CEO and Director of Forrester, each a qualified person as defined by National Instrument 43-101.

For more information, please contact:

James Walchuck, CEO and President of Zinc One at (604) 683 0911 or jwalchuck@zincone.com

Bill Williams, CEO of Forrester at (416) 364 7739 or bwilliams@forrestermetals.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Each of Zinc One and Forrester cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to each of Zinc One and Forrester’s limited operating history, ability to complete the proposed Transaction (including obtaining all necessary shareholder and regulatory approvals), ability to close the Private Placement Financing and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, neither Zinc One nor Forrester undertakes no obligation to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zinc One Resources Inc.

ReleaseID: 458341

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / Lilis Energy Inc. (NASDAQ: LLEX), will be a featured presenter at the MicroCap Conference at 10:30am, Track 3, on April 4th in New York City. Management will be available for one-on-one investor meetings throughout the conference.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th at 7:00AM, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com), and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

News compliments of ACCESSWIRE

About Lilis Energy,
Inc.

Lilis Energy, Inc. is a San Antonio-based independent oil and gas exploration and production company that operates in the Permian’s Delaware Basin and in the Denver-Julesburg (DJ) Basin, considered amongst the leading resource plays in North America. Lilis Energy’s primary business objective is to increase its Delaware Basin leasehold position, reserves, production and cash flows at attractive rates of return on invested capital in order to enhance shareholder value.

For more information please contact CORE IR: (516) 222-2560 or visit www.lilisenergy.com.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com

SOURCE: Lilis Energy Inc.

ReleaseID: 458283

Beaudon Spaulding Brings 20 Years of Digital Advertising & Proven Track Record of Driving Revenue

DEERFIELD BEACH, FL / ACCESSWIRE / March 28, 2017 / Golden Grail Technology Corp. (OTC PINK: GOGY) (“Golden Grail” or the “Company”), a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors, is extremely pleased to announce the appointment of Mr. Beaudon Spalding as Chief Marketing Officer of its subsidiary Accurate Venture Inc. Mr. Spalding is a highly seasoned marketing executive and will now lead the marketing department into the next phase of its expansion.

In February 2016, Golden Grail Technology acquired Accurate Venture, which develops and markets specific Hemp Cannabidiol supplement products. Accurate has a large marketing database of customers and offers monthly subscriptions for most of its product line.

Mr. Spaulding is an accomplished senior level executive with 20 years of digital advertising experience and a comprehensive knowledge of digital ad serving, behavioral analytics, online reporting, revenue optimization, sales management and technical implementations. He is known for being an innovative results-driven strategist with a proven track record of driving revenue.

Golden Grail’s Chief Executive Officer, Bill Fisher, commented, “Beaudon is a very strategic addition to the Accurate Venture team. He is highly recognized and well respected in the marketing industry and he has a sterling reputation to deliver success. With Beau’s experience and knowledge, we will make giant leaps forward with the company’s on-line marketing strategy.”

Mr. Spaulding is specialized in Behavioral Intent Marketing, Digital Ad Serving, Digital Advertising, Ad Serving Technologies (methods of delivery), and Ad Operations, In 2010 he co-founded a company called Klickthru, an Ad Serving Technology & Social Toolbar designed for Website Publishers. Klickthru resulted in a 200% higher yield over Google Ad-sense. In 2012, he established M2Talk, which managed call centers across the United States under an exclusive contract with the US Government.

Chief Marketing Officer, Beaudon Spaulding, stated, “It was love at first ‘site!’ I have not seen a business model in 10 years which represents such growth in such a short amount of time. Accurate Ventures resources of revenue is a beautiful addition to strengthening Golden Grail’s position in the market. With so much already in place, everyone is expecting a very strong start. In 2017, we look forward to an amazing story of success and continued ability to define Accurate Venture as a market leader. I am very excited about the outlook of the organization, its direction, and our accomplishments.”

About Golden Grail Technology Corp.

Golden Grail Technology Corp. (OTC PINK: GOGY) is a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors such as jewelry, health and personal care, beauty, electronics, pet and animal supplies, sports and games. Golden Grail’s mission is to utilize their network of industry experts, who specialize in targeting areas of business that can be accelerated with technology, in order to give small companies an opportunity to compete with industry giants.

For more information, please visit: http://goldengrailtechnology.com.

Forward-Looking Statements

Except for the historical and present factual information contained in this press release, the matters discussed in this press release, including statements identified by words such as “will,” “expected,” “plans,” and similar expressions are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements, including the factors described in filings with OTC Markets, including but not limited to discussion under the caption “Risk Factors.” Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s judgment solely as of the date hereof.

Contact Information

Hayden IR
(917) 658-7878
hart@haydenir.com

SOURCE: Golden Grail Technology Corp.

“>

ReleaseID: 458272

CARSON CITY, NV / ACCESSWIRE / March 28, 2017 / Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), announced that it has completed its registration process with U.S. Food and Drug Administration (“FDA”) and has initiated an application process to receive FDA clearance for use of its eBalance device as Class II non-exempt device.

The Company is also pleased to announce that its ongoing clinical observational trial (the “Trial”) is progressing as expected, and as of March 27th, 2017, the group of study participants had been increased to 21, with 18 subjects having received their first eBalance treatments. The Company expects that all 30 subjects will be initiated into the study by early April.

Current Observational Clinical Trial assesses the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following;

Insulin sensitivity

Diabetic neuropathy

Diabetic foot pain and numbness

Wound healing

Blood pressure

Kidney function

Any other changes reported by patients

Mr. McEnulty, the Company’s CEO, stated: “Our registration with the FDA is an exciting step forward, and I’m happy to see that our Observational Clinical Trial is also progressing as scheduled, which together will get us that much closer to reaching our end goal of helping people improve their lives and well-being.”

About Cell MedX Corp.

Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company’s newsletter, please go to www.cellmedx.com/media/newsletters/

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements

The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

Cell MedX Corp.
For further information visit: www.cellmedx.com.
Or phone: 1-844-238-2692

SOURCE: Cell MedX Corp.

ReleaseID: 458339